KLK3 and pachyonychia congenita: In this secondary analysis of a randomized clinical trial of nonmetastatic unfavorable-risk PC, we found that being younger than 70 years, having a PSA of 10 ng/mL or more, and having a Gleason score of 8 to 10 could be used to estimate the shorter time to PSA failure following initial treatment with ADT and RT with or without docetaxel.